Press Releases Galectin Therapeutics Inc.

Equities

GALT

US3632252025

Real-time Estimate Cboe BZX Other stock markets 12:42:42 2024-05-03 pm EDT			5-day change	1st Jan Change
3.385 ^USD	+0.45%		-3.77%	+100.00%

Mar. 29	Galectin Therapeutics Inc. Appoints Benjamin S. Carson as Member of the Board of Directors	CI
Mar. 29	Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Galectin Therapeutics : Corporate Presentation, April 2024	Apr. 17	PU
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension	Apr. 10	AQ
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis	Apr. 09	AQ
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update	Apr. 01	AQ
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update	Mar. 29	AQ
Galectin Therapeutics : Reports 2023 Financial Results and Provides Business Update - Form 8-K	Mar. 29	PU
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development	Mar. 12	AQ
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update	Nov. 13	AQ
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD	Nov. 03	AQ
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023	23-10-23	AQ
Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors	23-10-12	AQ
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension	23-10-04	AQ
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis	23-10-03	AQ
Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023	23-09-26	AQ
Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023	23-09-11	AQ
Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023	23-09-07	AQ
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update	23-08-14	AQ
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update	23-05-15	AQ
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023	23-04-27	AQ
Galectin Therapeutics Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases	23-04-19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Galectin Therapeutics Inc.

Equities

GALT

US3632252025

Press Releases

Filters